Chiron Diagnostics has 510(k) pending for ACS:Centaur automated chemiluminescence analyzer.
This article was originally published in The Gray Sheet
CHIRON DIAGNOSTICS ACS:CENTAUR ANALYZER 510(k) PENDING at FDA, the company says. Chiron unveiled the "next-generation" automated, chemiluminescence analyzer July 29 at the American Association of Clinical Chemistry meeting in Chicago; the firm expects to begin marketing through its direct sales force next spring in the U.S. and Europe.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.